We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
People vaccinated with Pfizer/BioNTech’s double-dose COVID-19 vaccine will likely need to receive a booster shot within a year of full inoculation, as well as an annual shot, according to Pfizer CEO Albert Bourla. Read More
Those treated with the antibody combination who suffered from symptomatic infection generally saw their symptoms end in one week vs. three weeks. Read More
Patients already participating in the study will continue to be assessed, the company said, adding it is developing an experimental inhaled formulation of the antiviral. Read More
New data from Moderna’s phase 3 COVID-19 vaccine trial have shown that the U.S. drugmaker’s two-dose inoculation remains highly effective against the virus six months after the second shot, including for severe infection, the company said Tuesday. Read More
More harmful side effects were found in clinical study reports submitted to regulators than in listings about the same medicines in trial registries or published studies. Read More
Regeneron Pharmaceuticals has said its COVID-19 antibody cocktail, REGEN-COV (casirivimab with imdevimab) reduced the risk of symptomatic infections by 81 percent in a late-stage trial. Read More
Patients given the JAK inhibitor were only 2.7 percent less likely than those who received standard of care to progress to ventilation or death. Read More
The FDA has found deficiencies in the biologics license application (BLA) data submitted for Provention Bio’s teplizumab, a monoclonal antibody being reviewed for delaying or preventing type 1 diabetes, and the agency’s evaluation of it is likely to be delayed as a result, the company said. Read More
For each patient group, approximately two-thirds of participants will be female, as most severe allergic reactions to vaccines have occurred in women. Read More
Eli Lilly’s and Incyte’s Janus kinase (JAK) inhibitor Olumiant (baricitinib) proved unable to significantly reduce progression to noninvasive ventilation for COVID-19 patients in a phase 3 trial, though the drug still managed to significantly reduce the risk of death. Read More